Image

The Effect of CUGP Fluid Management in Patients With Sepsis or Septic Shock

The Effect of CUGP Fluid Management in Patients With Sepsis or Septic Shock

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

This study aims to assess whether procedural critical ultrasonography guided precise fluid management (CUGP) can affect the clinical fluid management strategy and improve the outcomes of patients with sepsis or septic shock.

Description

This single-center parallel randomized controlled trial aims to assess whether procedural critical ultrasonography guided precise fluid management (CUGP) can affect the clinical fluid management strategy and improve the outcomes of patients with sepsis or septic shock. We planned to conduct this single-center trial in the intensive care unit (ICU) of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology in Wuhan, China. Patients, who are initially diagnosed with sepsis, will be assessed for eligibility immediately upon admission to the ICU. Then, eligible participants will be informed and randomly assigned to one of the two groups: the CUGP group or the usual care group, in a 1:1 ratio using block randomization. In the CUGP group, ultrasonographic assessment was performed by a team of trained critical ultrasonography physicians at enrollment, 1 hour, 3 hours, 6 hours, 12 hours, 24 hours, 48 hours, and 72 hours thereafter, respectively. The usual care group used conventional hemodynamic monitoring methods for monitoring and decision-making about fluid management. The enrolled patients received either CUGP or usual care fluid management within 72 hours of enrollment in the ICU, and followed by 60 days after randomization. The primary outcome was the 60-day all-cause mortality. The secondary outcomes included SOFA score at 24, 48, and, 72 hours after enrollment, fluid infusion volume, vasoactive drug dosage, incidence of serious adverse events related to fluid management, including new tracheal intubation, severe acute kidney injury, electrolyte disturbance, and organ ischemia (brain, myocardium, gastrointestinal tract, limbs), incidence of complications related to central venous and arterial puncture, acute left heart failure, and pulmonary edema, monitoring failure rates of CUGP group and usual care group, ICU and hospital length of stay, cost of ICU stay/hospitalization. This study adopts a standardized data collection and management system. The study implementer shall fill in the paper or electronic CRF.

Eligibility

Inclusion Criteria:

-

  1. Age ≥ 18 years old;

-

2. Estimated length of ICU stay ≥ 24 hours;

-

3. Diagnosis according to the Sepsis 3.0 criteria, which included:

  • a. suspected or confirmed infections supported by clinical evidence and/or positive microbiological findings;
  • b. the sepsis related organ failure assessment (SOFA) score ≥ 2.

Exclusion Criteria:

-

  1. Patients were pregnant woman;

-

2. Patients had acute coronary syndrome;

-

3. Patients had acute pulmonary edema;

-

4. Patients had status asthmatics;

-

5. Patients had malignant arrhythmia;

-

6. Patients had active gastrointestinal bleeding;

-

7. Patients had epileptic seizure;

-

8. Patients had drug poisoning;

-

9. Patients had severe burns;

-

10. Patients had contraindications of blood transfusion;

-

      11. Patients had intra-abdominal hypertension (intra-abdominal pressure increases
          continuously ≥ 12mmHg);

-

12. Patients had acute pulmonary embolism;

-

13. Patients had contraindications of leg raising;

-

      14. Patients had cardiac structural or functional abnormalities (left ventricular
          outflow tract obstruction, moderate-to-severe mitral regurgitation, aortic
          regurgitation), it would seriously affect the velocity time integral of left
          ventricular outflow tract;

-

15. Patients or their legal representatives refused active treatment;

-

16. Patients or their legal representatives refused to participate in this study;

-

17. Patients were participating in other interventional clinical trials.

Study details
    Sepsis

NCT06879249

Shusheng Li

26 April 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.